The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial( NCT03220178 ) assessed the effect of CANKADO-based electronic patient-reported outcome( ePRO ) assessment on quality of life( QoL ) in patients receiving palbociclib and an aromatase inhibitor, or paraplegic + fulvestrant, in hormone receptor-positive, human epidermal growth factor receptor 2 – negative locally advanced or metastatic breast cancer( MBC A medical device with a European Union registration called CANKADO PRO-React is an interactive, autonomous application that responds to patient self-reported observations.